Cetuximab in Refractory Skin Cancer Treatment
Open Access
- 1 January 2012
- journal article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 3, 257-261
- https://doi.org/10.7150/jca.3491
Abstract
Non-melanoma skin cancer is the most common malignancy in US, with an annual incidence of in excess of 1.5 million cases. In the majority of cases, locoregional treatment is curative and systemic therapy is not indicated. Platinum-based chemotherapy regimens have been used most commonly in refractory cases. The use of cetuximab, a monoclonal antibody targeting epidermal growth factor receptor [EGFR], has been reported for skin cancer treatment. This current study evaluated eight cases of locally advanced and refractory basal cell or squamous cell cancers which were treated with cetuximab. This is a retrospective study on eight patients who had received cetuximab for treatment of cutaneous carcinoma since 2007 at Southern Illinois University School of Medicine (SIU-SOM) Medical Oncology clinic. Three of the four patients with basal cell carcinoma and two of the four patients with squamous cell carcinoma maintained remission on treatment.. The main side effect was acneiform rash which required termination of treatment for one patient and dose reduction in another. The study indicates that cetuximab may have a beneficial role for patients with non-melanoma cutaneous carcinomas that are refractory to standard therapy.Keywords
This publication has 20 references indexed in Scilit:
- Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancerAmerican Journal of Otolaryngology, 2010
- Severe Radiation Dermatitis in Patients With Locally Advanced Head and Neck Cancer Treated With Concurrent Radiation and CetuximabAmerican Journal of Clinical Oncology, 2009
- Increased risk of high‐grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapyCancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Cutaneous head and neck squamous cell carcinoma metastatic to parotid and cervical lymph nodesHead & Neck, 2007
- Treatment recommendations in patients diagnosed with high‐risk cutaneous squamous cell carcinomaAustralasian Radiology, 2005
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- Cetuximab: An epidermal growth factor receptor chimeric human-murine monoclonal antibodyDrugs of Today, 2005
- Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Pharmacological background of EGFR targetingAnnals of Oncology, 2004